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BACKGROUND: Several recent studies demonstrated that microRNAs (miRNAs) are stably detectable in plasma/serum. We
hypothesised that plasma miRNAs concentrations contributed to potential biomarkers in patients with oesophageal squamous cell
carcinoma (ESCC).
METHODS: We selected three oncogenic miRNAs (miR-21, miR-184, miR-221) and one tumour suppressive miRNA (miR-375), which
are frequently reported in squamous cell carcinoma, as candidate targets for this plasma miRNA assay. This study was divided into
three steps: (1) Determination of appropriate plasma miRNAs in preliminary tests. (2) Evaluation of whether the plasma miRNA
assays could monitor tumour dynamics. (3) Validation study on the clinical application of plasma miRNA assays in 50 ESCC patients
and 20 healthy volunteers.
RESULTS: (1) In preliminary tests, the plasma level of miR-21 was significantly higher (P¼0.0218) and that of miR-375 (P¼0.0052) was
significantly lower in ESCC patients than controls. (2) The high plasma miR-21 levels reflected tumour levels in all cases (100%). The
plasma level of miR-21 was significantly reduced in postoperative samples (P¼0.0058). (3) On validation analysis, the plasma level of
miR-21 tended to be higher in ESCC patients (P¼0.0649), while that of miR-375 was significantly lower (Po0.0001) and the
miR-21/miR-375 ratio was significantly higher (Po0.0001) in ESCC patients than in controls. The value of the area under the
receiver-operating characteristic curve (AUC) was 0.816 for the miR-21/miR-375 ratio assay. Patients with a high plasma level of
miR-21 tended to have greater vascular invasion (P¼0.1554) and to show a high correlation with recurrence (P¼0.0164).
CONCLUSION: Detection of circulating miRNAs might provide new complementary tumour markers for ESCC.
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Oesophageal cancer is the eighth most common cancer in the world
and is the sixth leading cause of cancer mortality (Enzinger and
Mayer, 2003). There are two histologic types of oesophageal cancer,
but oesophageal squamous cell carcinoma (ESCC) accounts for
B90% of oesophageal carcinomas diagnosed in Asian countries
(Hiyama et al, 2007). Although surgical techniques and perioperative
management have progressed, ESCC remains one of the most
aggressive carcinomas of the gastrointestinal tract. Therefore, primary
tumours must be detected at an early stage, and recurrent disease
must be diagnosed when it is still minimal or clinically occult, in
o r d e rt oi m p r o v et h ec u r er a t e sf o rp a t i e n t sw i t hE S C C .
As finding molecular targets for ESCC treatment might help to
improve the survival of patients with this lethal disease, studies
have attempted to identify the biological factors involved in the
malignant potential of ESCC. Several recent studies have elucidated
that certain molecules, such as p53, cyclin D1 and FAS, have
important roles in tumourigenesis and the development of the
ESCC (Hollstein et al, 1990; Ade ´laide et al, 1995; Gratas et al,
1998). In clinical setting, however, few molecules have been
assayed as therapeutic and/or diagnostic biomarkers. Conven-
tional serum tumour markers, such as carcinoembryonic antigen
(CEA) and squamous cell carcinoma antigen (SCC), have been
used as convenient diagnostic assays (Kosugi et al, 2004; Mroczko
et al, 2008) for early detection and monitoring tumour dynamics of
ESCC. These serum tumour markers, however, lack sufficient
sensitivity and specificity to facilitate early detection of cancer.
Therefore, the significance of detecting novel biomarkers using a
less invasive diagnostic assay for ESCC should be emphasised.
MicroRNAs (miRNAs), which are small and non-coding RNAs,
regulate the translation of specific protein-coding genes. Since
their discovery in 1993 (Lee et al, 1993), altered expressions of
miRNAs have been associated with several diseases, and tumour
miRNAs are involved in tumourigenesis and the development of
various cancers. Recent several studies demonstrated that miRNAs
are stably detectable in plasma/serum (Calin and Croce, 2006;
Chen et al, 2008; Filipowicz et al, 2008). Tumour-derived miRNAs
are resistant to endogenous ribonuclease activity because these
may be packaged by some kinds of secretory particles including
apoptotic bodies and exosomes in plasma/serum (Hasselmann
et al, 2001; Mitchell et al, 2008; Cocucci et al, 2009; Kosaka et al,
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s2010). Therefore, miRNAs can be present in a remarkably stable
form (Mitchell et al, 2008) and the expression level of serum
miRNAs is reproducible and consistent among individuals (Chen
et al, 2008; Mitchell et al, 2008). Furthermore, secretory vesicles
including miRNAs can function as intercellular transmitters
(Valadi et al, 2007; Skog et al, 2008; Rechavi et al, 2009). Indeed,
many studies have demonstrated the presence of circulating
miRNAs and their potential use as novel biomarkers of cancers,
such as prostate cancer (Mitchell et al, 2008), leukaemia (Lawrie
et al, 2008), oral cancer (Wong et al, 2008), pancreatic cancer
(Wang et al, 2009), colorectal cancer (Ng et al, 2009), ovarian
cancer( Resnick et al, 2009), lung cancer ( Hu et al, 2010), breast
cancer (Heneghan et al, 2010 ) including our report in gastric
cancer (Tsujiura et al, 2010). These findings should open up a new
and interesting field in the screening and monitoring of ESCC
patients. However, to date, there has not been any report on the
role of circulating miRNAs in plasma of patients with ESCC.
In this study, we selected three oncogenic miRNAs (miR-21,
miR-184, miR-221) and one tumour suppressive miRNA
(miR-375), which are frequently reported in squamous cell
carcinoma, as candidate targets for this plasma miRNA assay.
(Chang et al, 2008; Feber et al, 2008; Guo et al, 2008; Wong et al,
2008; Avissar et al, 2009). We hypothesised that plasma miRNAs
concentrations would contribute to potentially useful biomarkers
in patients with ESCC. Namely, we investigated whether assay of
plasma circulating miRNAs could detect cancers by comparing
findings in ESCC patients and healthy volunteer controls. Then, we
evaluated whether the concentration of circulating miRNAs in
plasma samples could screen cancer patients, monitor tumour
dynamics and whether the levels were associated with clinico-
pathological factors in ESCC patients.
PATIENTS AND METHODS
Patients and samples
Between November 2008 and April 2009, for test scale analysis,
20 preoperative plasma samples were collected from consecutive
patients with ESCC, who underwent curative esophagectomy
(R0 or R1) at Kyoto Prefectural University of Medicine, as well
as from 10 healthy volunteers. After the initial quantitative analysis
of plasma miRNAs, to validate whether plasma miRNAs are related
to primary ESCC lesions, formalin-fixed paraffin-embedded
tumour samples were also collected from ESCC patients in order
to compare the expressions of miRNAs in primary lesions with
those in plasma samples (see the section ‘Relationship between the
miRNAs in plasma and primary ESCC tissues’ described below).
Furthermore, paired plasma samples were serially collected from
eight patients before and 1 month after esophagectomy, showing
high miRNAs in plasma in the initial series. For further validation
analyses, preoperative plasma samples were collected from another
30 patients with ESCC as well as from another 10 healthy
volunteers. Thus, between November 2008 and March 2010, a
total of 50 patients with ESCC and 20 healthy volunteers were
enroled in this study.
After obtaining informed consent, 7ml of peripheral blood was
obtained from each patient before any surgery and from healthy
volunteer controls. Immediately after collection, the blood samples
were subjected to isolation of cell-free nucleic acids using a 3-spin
protocol (1500r.p.m. for 30min, 3000r.p.m. for 5min, 4500r.p.m.
for 5min) to prevent contamination by cellular nucleic acids.
Plasma samples were then stored at  801C until further
processing. The resected ESCC specimens were fixed in buffered
formalin and embedded in paraffin for pathological examination
by standard methods. Macroscopic and microscopic classification
of tumours was based on the UICC/TMN staging system (Sobin
et al, 2009).
RNA extraction from plasma samples
Total RNA was extracted from 400ml of plasma using mirVana
PARIS Kit (Ambion, Austin, TX, USA), and finally eluted into
100ml of preheated (951C) elution solution according to the
manufacturer’s protocol. Using formalin-fixed paraffin-embedded
tissues, total RNA was extracted from four slices of 15mm
thickness (total 60mm in thickness) using Recover All Total
Nucleic Acid Isolation Kit (Ambion), and then eluted into 60mlo f
elution solution according to the manufacturer’s protocol.
Protocols for the detection of miRNAs
We selected three candidates for oncogenic miRNAs such as miR-21,
miR-184 and miR-221, which were frequently expressed in either
ESCC or solid cancers associated with squamous cell carcinoma.
Although miR-375 was described as a candidate for tumour-
suppressor miRNA in previous reports (Chang et al, 2008; Feber
et al, 2008; Guo et al, 2008; Wong et al, 2008; Avissar et al, 2009),
in plasma assay of miRNAs, stable internal controls of plasma
miRNAs have not been previously reported. Therefore, we utilised
the miR-375 as an internal control in plasma miRNA assay.
The amounts of miRNAs were quantified in duplicate by
qRT–PCR using human TaqMan MicroRNA Assay Kits (Applied
Biosystems, Foster City, CA, USA). Reverse transcription reaction
was carried out with the TaqMan MicroRNA Reverse Transcription
Kit (Applied Biosystems) in 15ml containing 5ml of RNA extract,
0.15ml of 100mM dNTPs, 1ml of Multiscribe Reverse Transcriptase
(50Uml
 1), 1.5mlo f1 0  reverse transcription buffer, 0.19mlo f
RNase inhibitor (20Uml
 1), 1ml of gene-specific primer and 4.16ml
of nuclease-free water. For the synthesis of cDNA, the reaction
mixtures were incubated at 161C for 30min, at 421C for 30min, at
851C for 5min and then held at 41C. Then, 1.33ml of the cDNA
solution was amplified using 10ml of TaqMan 2  Universal PCR
Master Mix with no AmpErase UNG (Applied Biosystems), 1mlo f
gene-specific primers/probe and 7.67ml of nuclease-free water in a
final volume of 20ml. Quantitative PCR was run on a 7300 Real-
time PCR system (Applied Biosystems) and the reaction mixtures
were incubated at 951C for 10min, followed by 40 cycles of 951C
for 15s and 601C for 1min. The cycle threshold (Ct) values were
calculated with SDS 1.4 software (Applied Biosystems).
The amounts of plasma miRNAs were calculated on a standard
curve constructed using synthetic miRNAs, mirVana miRNA
Reference Panel (Ambion). The standard reference miRNAs were
amplified for each reaction. However, the expression of miRNAs
from tissue samples was normalised using the 2
 DDCTmethod
relative to U6 small nuclear RNA (RNU6B). The DCt was calculated
by subtracting the Ct values of RNU6B from the Ct values of the
miRNAs of interest. The DDCt was then calculated by subtracting
DCt of the surrounding normal gastric epithelium from DCt of
cancer tissues. Fold change in the gene was calculated by the
equation 2
 DDCt (Livak and Schmittgen, 2001; Pfaffl, 2001).
Statistical analysis
Mann–Whitney test was used to compare differences in plasma
miRNA concentration and miRNA ratio between the cancer group
and the healthy group, and Wilcoxon test was used to compare the
paired plasma samples obtained before and 1 month after
esophagectomy. P-value o0.05 was considered significant.
w
2 square test or Fisher’s exact probability test was used to
evaluate the correlations between the results of the plasma
mirRNA concentration and clinicopathological factors. Receiver-
operating-characteristic (ROC) curves and the area under the ROC
curve (AUC) were used to assess the feasibility of using plasma
miRNA as diagnostic tools for detecting ESCC. Younden index was
used to determine the cutoff value for the plasma miRNAs
concentration (Akobeng, 2007).
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Evaluation of quantitative RT–PCR for measuring the
miRNAs in plasma sample and test scale study to
determine the appropriate plasma miRNAs in ESCC
To evaluate the appropriateness of this plasma assay, we first
conducted amplification by real-time RT–PCR assay of a 10-fold
serial dilution of the mirVana miRNA Reference Panel. The
linearity of the quantitative RT–PCR was confirmed from the
concentrations of 1 to 0.0001fmol of each synthetic miRNAs, such
as miR-21, miR-184, mir-221 and mir-375 (R
2¼0.999, 0.996, 0.988
and 0.999, respectively), between the logarithm of the amount of
input miRNAs and the Ct values (Figure 1). Using this assay,
circulating miRNAs such as miR-21, mir-221 and mir-375 were
detectable in all samples from 20 ESCC patients and 10 healthy
volunteers. However, miR-184 could not be detected in half of the
samples (50%) because its concentration in cancer patients was
extremely low despite being detected in all of the healthy
volunteers. However, the concentrations of miR-21 were signifi-
cantly higher in plasma from ESCC patients than those in healthy
volunteers (P¼0.0218) (Figure 2A). The concentration of mir-221
did not demonstrate any significant differences between plasma
from ESCC patients and that from healthy volunteers (P¼0.4919)
(Figure 2B). The detectable concentrations of plasma miR-184 in
10 ESCC patients were significantly lower than those in plasma
from healthy volunteers (P¼0.0032) (Figure 2C). Furthermore, the
concentrations of miR-375 were significantly lower in plasma from
ESCC patients (P¼0.0052) (Figure 2D). In oncogenic miRNAs, we
hypothesised that plasma miRNAs presented a high level reflecting
the tumour miRNA expression in ESCC patients. However, we
excluded two miRNAs such as miR-184 and miR-221 for further
analyses because these two miRNAs were not sufficiently elevated
in the plasma of cancer patients. Therefore, we selected miR-21
and miR-375 as candidates for further analyses.
Evaluation of whether the concentrations of plasma
miRNAs such as miR-21 and miR-375 could monitor
tumour dynamics
We analysed the expressions of miRNAs in ESCC tissues and
adjacent normal oesophageal tissues in seven ESCC patients
showing high concentrations of miR-21 and in four ESCC patients
showing low concentrations of miR-21 compared with those in
healthy volunteers. Furthermore, seven ESCC patients showing
lower concentrations of miR-375 and four ESCC patients showing
higher concentrations were analysed. All of the miRNAs obtained
from formalin-fixed paraffin-embedded tissues were amplified,
and found to be of good quality for amplification (data not shown).
Then, we compared the tissue results with plasma results in the
miRNA assay. Consequently, miR-21 showed higher expressions in
primary ESCC tissues than in normal mucosa in all 11 patients
analysed (100%) (Supplementary Table S1), while miR-375 showed
lower expressions in primary ESCC tissues than in normal mucosa
in all 11 patients (100%)(Supplementary Table S2). Despite a
higher expression of tumour miR-21, the plasma miR-21
concentration was low in four ESCC patients (Supplementary
Table S1). Similarly, the plasma miR-375 concentration demon-
strated normal expression levels despite lower expressions of
tumour miR-375 in four ESCC patients (Supplementary Table S2).
These findings indicated that the concentration of plasma miRNAs
reflected to some extent their expression in tumour. Then, the
concentrations of miR-21 were analysed in paired pre- and
postoperative plasma samples from eight ESCC patients who
underwent curative esophagectomy. The concentrations of plasma
miR-21 were significantly reduced in postoperative samples
compared with the levels in the preoperative samples
(P¼0.0058) (Figure 3A). In one typical patient, re-elevation of
plasma miR-21 concentration was found at recurrence after
surgery despite the lack of any elevation in conventional serum
tumour marker such as CEA (Figure 3B).
Validation study on clinical application as a diagnostic
plasma biomarker
In total, 50 ESCC patients and 20 healthy volunteers were included
in the validation study; there were 15 patients with TNM stage 0–I,
10 with stage II, 24 with stage III and 1 with stage IV. We analysed
two miRNAs, miR-21 and miR-375, for the validation study. The
plasma concentrations of miR-21 tended to be higher in ESCC
patients than in controls (P¼0.0649) (Figure 4A), while the
concentration of miR-375 was significantly lower in ESCC patients
than in controls (Po0.0001) (Figure 4B). To investigate more
sensitive diagnostic biomarkers in plasma, we analysed the ratio of
circulating miRNAs levels, dividing the plasma concentrations of
miR-21 by that of miR-375, as a combined biomarker. As a result,
the ratio of miR-21/miR-375 was significantly higher in ESCC
patients than that in controls (Po0.0001) (Figure 4C). Supple-
mentary Figure S1 shows ROC curves for both plasma miR-21 and
miR-375, and the area under the curve (AUC) were 0.618 and
0.807, respectively. The ROC analysis showed the greatest AUC of
0.816 for the ratio of miR-21/miR-375 (Figure 5).
Correlation between the results of plasma miRNAs and
clinicopathological factors
We examined the association of plasma miRNAs concentrations
(miR-21, miR-375) with clinicopathological factors in 50 con-
secutive ESCC patients. To detect cutoff points that could
discriminate cancer patients and normal volunteers using these
plasma mirRNA concentrations, we utilised ROC curves with the
Younden index (Akobeng, 2007). The cutoff concentrations for
miR-21 and miR-375 were 0.2227 and 0.00334amolml
 1, respec-
tively. Consequently, patients with high plasma miR-21 concentra-
tion showed a tendency towards vascular invasion (P¼0.1554) and
there was a correlation with disease recurrence (P¼0.0164)
(Table 1). However, there was no significant correlation between
the concentration of plasma miR-375 and clinicopathological
factors (data not shown).
35
30
25
miR-21
miR-184
15
20
miR-375
miR-221
10
C
t
 
v
a
l
u
e
0
5
Log concentration
1 0 –1 –2 –3 –4 –5
Figure 1 Standard curve of miR-21, miR-184, miR-221 and miR-375
using synthetic microRNAs. Ten-fold serial dilutions of synthetic microRNA
were used to generate the standard curves. Linearity was confirmed within
these concentrations, ranging from 1 to 0.0001fmol. (miR-21: y¼ 3.6855x
þ14.128 (R
2¼0.9998), miR-184: y¼ 3.6005xþ14.877(R
2¼0.9960),
miR-221: y¼ 3.5932xþ13.757 (R
2¼0.9880), miR-375: y¼ 3.7384x
þ13.242 (R
2¼0.9996)).
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A non-invasive assay using circulating nucleic acids opens up a
new and interesting field in the screening and monitoring
of cancer patients. Numerous genetic and epigenetic alterations
are known to be involved in tumourigenesis and the progression
of various cancer tumours. Several studies have identified tumour-
specific alterations in the plasma/serum nucleic acids of cancer
patients, and have demonstrated the potential of plasma
circulating nucleic acids as new non-invasive biomarkers in
patients with various cancers (Sidransky, 1997; Anker et al, 2001;
Taback and Hoon, 2004; Chan and Lo, 2007; Diehl et al,
2008). During the last decade, non-coding RNAs, so-called
miRNAs, have also been demonstrated to regulate gene expression
by targeting mRNAs for translational repression or cleavage.
Consequently, these miRNAs have recently become known as new
factors related to oncogenesis and the progression of various
cancer tumours (He et al, 2005, 2008; Lu et al, 2005; Calin and
Croce, 2006).
MicroRNAs have been proven to contribute to carcinogenesis
and may provide new therapeutic strategies such as biomarkers
and therapeutic targets for cancers. Particularly, studies investigat-
ing plasma miRNAs comprise an extremely promising field for
clinical application. Tumour-derived miRNAs was first described
in plasma by Mitchell et al (2008). Plasma miRNAs such as
miR-141 could efficiently identify prostate cancer patients and
show the potential to be new biomarkers. They also demonstrated
the high stability of plasma miRNAs after prolonged incubation at
room temperature and/or multiple freezing–thawing processes. In
addition to this high stability, the characteristics of miRNAs such
as tissue-specific miRNA signatures and the availability of many
copies per cell would indicate potential advantages as biomarkers
compared with those of other nucleic acids, such as circulating
DNA and mRNA. In fact, accumulating reports also suggest the
potential of miRNAs in the early detection of patients with several
malignancies, such as prostate cancer (Mitchell et al, 2008),
lymphoma (Lawrie et al, 2008), oral cancer (Wong et al, 2008),
pancreatic cancer (Wang et al, 2009), colorectal cancer (Ng et al,
2009), ovarian cancer (Resnick et al, 2009), lung cancer (Hu et al,
2010), breast cancer (Heneghan et al, 2010) and gastric cancer
(Tsujiura et al, 2010). To date, however, there has been no report
on the role of circulating miRNAs in plasma of patients with
oesophageal cancer. These findings prompted us to further
investigate the usefulness of miRNAs in patients with oesophageal
cancers. In this study, we selected four candidate miRNAs, three
oncogenic miRNAs and one tumour-suppressor miRNA, based on
their involvement in tumour development and progression of
squamous cell carcinoma.
Although some investigators have determined quantities of
plasma miRNAs by comparing internal control miRNAs (Ng et al,
2009; Resnick et al, 2009), it remains controversial as to which
miRNAs are suitable as internal control for plasma assay.
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Figure 2 Plasma miRNAs concentration in the initial analysis. Real-time RT–PCR assay, circulating plasma miRNAs such as miR-21, miR-221 and miR-375
excepting miR-184 were detectable and amplified in all samples from 20 ESCC patients and 10 healthy volunteers. Although it was detected in all healthy
volunteers, miR-184 could not be detected in half of samples (50%) because its concentration in cancer patients was extremely low. The concentrationso f
miR-21 tended to be higher in plasma from ESCC patients than in that from healthy controls (P¼0.0218) (A). Whereas, the concentration of miR-221 did
not show any significant differences between plasma from ESCC patients and that from healthy volunteers (P¼0.4919) (B). The detectable concentrations
of plasma miR-184 in 10 ESCC patients were significantly lower than those in plasma from healthy volunteers (P¼0.0032) (C). The concentrations of
miR-375 were significantly lower in plasma from ESCC patients (P¼0.0052) (D). The upper and lower limits of the boxes and the lines inside the boxes
indicate the 75th and 25th percentiles and the median, respectively. The upper and lower horizontal bars denote the 90th and 10th percentiles, respectively.
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logarithm of the amount of input synthetic miRNA and the Ct
value on real-time PCR, as well as the feasibility of extracting total
RNA and amplifying specific miRNA in plasma samples. Based on
these findings, we utilised the absolute concentration method for
measuring plasma miRNAs in this study. Consequently, as a larger
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Figure 3 (A) Comparison of plasma miR-21 and miR-375 concentrations between pre- and postoperative samples from ESCC patients. The
concentration of plasma miR-21 was significantly decreased in the postoperative samples compared with the levels in preoperative samples (P¼0.0058)
(A). However, the postoperative plasma miR-375 concentration was not significantly different from the preoperative plasma concentration (P¼0.2626) (B).
(B) Changes of the plasma miR-21 concentration and the serum CEA concentration in one patient. In one patient, who developed recurrence after surgery
without any elevation of conventional serum tumour markers such as CEA, re-elevation of plasma miR-21 concentration was found at recurrence. The
boldface lines are cutoff concentrations of miR-21 and CEA.
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screening and monitoring of oesophageal cancer.
Furthermore, we investigated whether plasma oncomir such as
miR-21 could be released from primary oesophageal tumours.
Comparison between the expression of miR-21 in plasma and
primary tumour tissue demonstrated that plasma and primary
ESCC tissue samples showed that the high level of plasma miR-21
represented higher expressions in primary ESCC tissues than in
normal mucosa in all patients analysed (100%) (Supplementary
Table S1). Some patients, however, showed a different pattern of
miRNA levels, low plasma miR-21 with a high expression in ESCC
tissue. This finding indicated that the expression of plasma miR-21
reflected tumour dynamics to some extent. However, the
discrepancies remain to be clarified. One possible explanation
for this finding may be owing to the heterogeneity of the primary
tumours. However, why tumour miR-21 expression does not
influence plasma miR-21 expression in every case remains unclear.
We also measured circulating miRNAs in paired plasma obtained
before and 1 month after surgical removal of the tumours, in order
to confirm tumour release of the circulating miRNAs. As a result,
the concentrations of miR-21 were significantly reduced post-
operatively in patients with high preoperative plasma miR-21.
These findings were similar to those in gastric cancer patients in
our previous report (Tsujiura et al, 2010). Concerning monitoring
cancer, in one representative patient with recurrence, re-elevation
of plasma miR-21 concentration was found at recurrence after
surgery, although there was no elevation of conventional serum
tumour markers such as CEA. These findings also clearly
demonstrated that the plasma concentration of miR-21 reflects
tumour dynamics and is available as a new plasma biomarker for
monitoring cancer. Although the kinetics and metabolism of
plasma miRNAs have not yet been clearly elucidated, this issue is
currently under evaluation.
To evaluate the possibility for clinical application as novel
biomarkers, we performed a large-scale study by increasing the
number of plasma samples from ESCC patients and healthy
volunteers in order to validate the diagnostic potential of selected
miRNAs such as miR-21and miR-375. We found that the plasma
concentrations of miR-21 tended to be higher in ESCC patients than
in healthy volunteers. However, the concentration of miR-375 was
significantly lower in ESCC patients than in healthy volunteers,
contrary to our expectation. Previously, we found that a tumour
suppressor let-7a showed a lower plasma expression level in gastric
cancer patients (Tsujiura et al, 2010). We also found that tumour
suppressive miR-375 showed a lower plasma expression level in
ESCC patients than in healthy volunteers. Surprisingly, comparison
between the expression of miR-375 in plasma and primary ESCC
tissue samples showed similar tendencies in almost all cases. As
circulating miRNAs are considered to have been released from
cancer tissues as well as from normal tissues, the majority of these
miRNA are expected to have originated from normal tissues. Our
findings of some tumour-suppressor miRNAs in cancer patients
seemed strange from this perspective. Several recent reports have
suggested that plasma miRNAs might be protected in a complex with
other molecules, such as exosomes, proteins and lipids (Valadi et al,
2007, Mitchell et al, 2008). The protection of miRNAs might have
greater effect in ESCC patients than healthy volunteers. An
alternative hypothesis is that a lower plasma expression of certain
tumour-suppressor miRNAs might be due to alterations in miRNAs
expressions in normal tissues of cancer patients by unknown
mechanisms. Kosaka et al (2010) proposed a novel hypothesis that
miRNAs could be conducive to the maintenance and surveillance
system against cancer progression. During the initial stage of
tumourigenesis, downregulation of miRNAs in cancer cells is
compensated by the surrounding cells that supply exosomes
containing the decreased miRNAs. However, once the surrounding
cells can no longer meet this demand, cancer cells enter an advanced
stage. Interestingly, this theory would explain our clinical findings.
Taken together, the secreted and circulating miRNAs could have
a pivotal role as signalling molecules in both physiological events
and carcinogenesis. These findings highlight their usefulness as
biomarkers and potential therapeutic targets in ESCC.
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Figure 5 Receiver-operating characteristic (ROC) curve analysis of the
miR-21/miR-375 assay ratio for detecting ESCC patients. The ROC analysis
showed the greatest AUC of 0.816 for the ratio of miR-21/miR-375.
Table 1 Correlation between plasma miR-21 concentration and
clinicopathological factors in consecutive 50 ESCC patients
Plasma miR-21 concentration
Variable n High Low P-value
a
Total 50 24 (48.0%) 26 (52.0%)
Sex
Male 44 21 (47.7%) 23 (52.3%) 0.6688
Female 6 3 (50.0%) 3 (50.0%)
Age
o65 25 12 (48.0%) 13 (52.0%) 1
65p 25 12 (48.0%) 13 (52.0%)
Lymphatic invasion
Negative 34 16 (47.1%) 18 (52.9%) 0.9130
Positive 16 8 (50.0%) 8 (50.0%)
Venous invasion
Negative 35 14 (40.0%) 21 (60.0%) 0.1554
Positive 15 10 (66.7%) 5 (33.3%)
T stage
b
T0/1/2 25 12 (48.0%) 13 (52.0%) 1
T3/4 25 12 (48.0%) 13 (52.0%)
N Stage
b
Negative 22 9 (40.9%) 13 (59.1%) 0.5455
Positive 28 15 (53.6%) 13 (46.4%)
Stage
b
0–II 25 13 (52.0%) 12 (48.0%) 0.5712
III–IV 25 11 (45.0%) 14 (55.0%)
Recurrence
Negative 39 15 (38.5%) 24 (61.5%) 0.0164
Positive 11 9 (81.8%) 2 (18.2%)
aP values are from w
2 or Fisher’s exact probability test and were considered significant
at 0.05.
bTNM classification. Statistically significant or tended values are in boldface type.
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sDetermining the expression ratios of genes or miRNAs has been
reported to be a useful technique for improving the diagnostic
potential of such markers (Gordon et al, 2002; Avissar et al, 2009).
Therefore, we also investigated miRNA expression ratios by
dividing the plasma concentration of upregulated miR-21 by that
of downregulated miR-375 in order to improve the sensitivity and
specificity of plasma miRNA assay for use as diagnostic
biomarkers. Then, the ratio of miR-21/miR-375 showed the
highest AUC value of 0.816 in the present study, and would be
satisfactory for clinical application. The expression ratio of
miR-21/miR-375 in plasma could distinguish ESCC patients
from healthy control patients with 88% sensitivity and 70%
specificity.
We present here a framework to assess tumour characteristics
by non-invasive plasma miRNA assay. This study is the first report
of circulating miRNAs in plasma of patients with ESCC and our
findings demonstrate that cancer-associated miRNAs in plasma
can potentially serve as novel non-invasive biomarkers for ESCC.
However, many issues should be addressed before these findings
can be translated into a clinically useful, non-invasive screening
strategy for ESCC. These issues are currently under evaluation in a
large number of studies, including other miRNA candidates in
ESCC. In conclusion, this study clearly demonstrated that plasma
miRNAs such as miR-21 and miR-375 provide useful biomarkers
for screening ESCC, monitoring tumour dynamics and predicting
associated clinical factors of ESCC. This technology could facilitate
clinical decision-making and be applicable to tailor-made medicine
for each individual.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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